Structure Therapeutics (GPCR) Cash from Investing Activities (2022 - 2026)

Structure Therapeutics' Cash from Investing Activities history runs 5 years deep, the most recent figure standing at -$496.9 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 1560.19% year-over-year to -$496.9 million; the TTM figure through Mar 2026 stood at -$441.2 million (down 35.21% YoY), while the FY2025 annual figure was $89.8 million, up 125.02% from the prior year.
• Cash from Investing Activities was -$496.9 million for Q1 2026 at Structure Therapeutics, down from $56.1 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $56.1 million in Q4 2025 to a low of -$496.9 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged -$64.5 million across 5 years, with a median of -$16.7 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities tumbled 1847.84% in 2023, then surged 2300.07% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at $10.3 million in 2022, then sank by 1847.84% to -$180.7 million in 2023, then soared by 118.39% to $33.2 million in 2024, then soared by 68.93% to $56.1 million in 2025, then plunged by 985.19% to -$496.9 million in 2026.
• The last three Cash from Investing Activities figures came in at -$496.9 million (Q1 2026), $56.1 million (Q4 2025), and -$49.3 million (Q3 2025), per Business Quant data.